Alloksys's RESCAP platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP administration is expected to significantly attenuate the overall ischemic clinical condition of these…
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt, UniMed Wien Vienna, Almazov Heart…
Computational model clarifies immune response during cardiac surgery 11 October 2018 A research team led by Peter Sloot, professor of Complex Adaptive Systems at the UvA, has managed to pinpoint…
After approval was obtained in October 2018, the kidney transplantation study with RESCAP platform technology under supervision of PI Dr Joost van der Heijden from VUmc Amsterdam found its "First…
AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. Among these diseases are unmet medical need applications in Neurodegenerative diseases Parkinson and Alzheimer as…
Following the start of patient inclusion in Europe, the first Asian center participating international study APPIRED lll has started patient recruitment. The National University Heart Centre, Singapore (NUHCS) is the…
Wageningen, 16 November 2017- Alloksys Life Sciences announced today that its international APPIRED lll clinical study has started with inclusion of the first patient in Eindhoven, the Netherlands. Patients undergoing…